About High mobility group nucleosome-binding domain-containing protein 5
High mobility group nucleosome-binding domain-containing protein 5 (HMGN5) is a protein
from Homo sapiens identified by UniProt accession
P82970, 282 residues long.
MolForge cross-references it against 0 known binders and
71 disease associations.
Target properties
| Protein name | High mobility group nucleosome-binding domain-containing protein 5 |
| UniProt accession | P82970 |
| Gene | HMGN5 |
| Organism | Homo sapiens |
| Length | 282 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (71)
Diseases linked to this target (Open Targets).
- urinary bladder carcinoma · score 0.09
- nonpapillary renal cell carcinoma · score 0.08
- glioblastoma · score 0.07
- renal cell carcinoma · score 0.07
- non-small cell lung carcinoma · score 0.05
- agammaglobulinemia 10, autosomal dominant · score 0.05
- immunodeficiency 18 · score 0.05
- isolated agammaglobulinemia · score 0.05
- severe combined immunodeficiency due to CTPS1 deficiency · score 0.05
- osteosarcoma · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P82970-F1 | alphafold | PREDICTED | 52.85 | — |
Amino-acid sequence (282 residues)
MPKRKAAGQG DMRQEPKRRS ARLSAMLVPV TPEVKPKRTS SSRKMKTKSD MMEENIDTSA QAVAETKQEA VVEEDYNENA KNGEAKITEA PASEKEIVEV KEENIEDATE KGGEKKEAVA AEVKNEEEDQ KEDEEDQNEE KGEAGKEDKD EKGEEDGKED KNGNEKGEDA KEKEDGKKGE DGKGNGEDGK EKGEDEKEEE DRKETGDGKE NEDGKEKGDK KEGKDVKVKE DEKEREDGKE DEGGNEEEAG KEKEDLKEEE EGKEEDEIKE DDGKKEEPQS IV
Explore High mobility group nucleosome-binding domain-containing protein 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets